Jeevan Scientific Reports Strong FY26 Profit Growth, Completes Capital Raise

Standalone profit after tax ₹1.65 crore; Consolidated profit ₹1.03 crore.

Reader Takeaway: Profitability significantly improved while capital raising activities were completed; new labour codes pose a future watch point.

What just happened

Jeevan Scientific Technology Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a substantial increase in profitability on both standalone and consolidated bases.

Standalone profit after tax (PAT) surged to ₹1.65 crore (₹165.01 lakh) for FY26, a significant jump from ₹0.74 crore (₹73.67 lakh) in FY25. On a consolidated basis, PAT rose to ₹1.03 crore (₹103.33 lakh) from ₹0.06 crore (₹5.90 lakh) in the previous fiscal year.

Revenue from operations also saw growth, with standalone revenue at ₹53.93 crore in FY26, up from ₹43.61 crore in FY25. Consolidated revenue increased to ₹61.54 crore from ₹46.84 crore.

The company also completed several corporate actions during the year, including the allotment of 4,085,000 equity shares and 3,000,000 partly paid convertible warrants to the promoter group, and 500,000 warrants to non-promoters.

Why this matters

The strong profit growth indicates improved operational efficiency and market performance for Jeevan Scientific. The successful capital raising through preferential allotment could provide the company with necessary funds for expansion or working capital, which is positive for future growth prospects. An unmodified auditor's opinion adds credibility to the financial reporting.

The backstory

Jeevan Scientific Technology operates in the Clinical Research Services segment. Its financial performance in the past year, FY25, showed a much lower profit margin. The company's focus remains on its single reportable business segment.

What changes now

Investors can expect potential changes in the shareholding structure due to the recent allotments. The improved financial health may lead to increased investor confidence. The company will need to implement accounting changes related to the new Labour Codes, which could impact future expense recognition.

Risks to watch

A key watch point for the company is the implementation of four new Labour Codes. This regulatory change requires immediate recognition of past service costs in the profit and loss statement, which could affect future financial metrics and profitability. Investors need to monitor how Jeevan Scientific manages these accounting adjustments.

Peer comparison

Information on specific peers within the Clinical Research Services segment for direct comparison is not provided in the filing.

Context metrics (time-bound)

• Standalone PAT FY26: ₹1.65 crore (vs. ₹0.74 crore in FY25)
• Consolidated PAT FY26: ₹1.03 crore (vs. ₹0.06 crore in FY25)
• Equity Shares Allotted: 4,085,000
• Warrants Allotted: 3,500,000 (Promoter & Non-Promoter)

What to track next

Investors should closely monitor the financial impact of the new Labour Codes on Jeevan Scientific's expenses and profitability in the upcoming quarters. The utilization of funds raised through the preferential allotment will also be a key factor to observe.